Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mechanisms of Primary Drug Resistance in FGFR1 -Amplified Lung Cancer

19 Jun 2017

Abstract excerpt

Abstract Purpose: The 8p12-p11 locus is frequently amplified in squamous cell lung cancer (SQLC); the receptor tyrosine kinase fibroblast growth factor receptor 1 (FGFR1) being one of the most prominent targets of this amplification. Thus, small molecules inhibiting FGFRs have been employed to treat FGFR1-amplified SQLC. However, only about 11% of such FGFR1-amplified tumors respond to single-agent FGFR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Fibroblast Growth Factor Research
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28630215
DOI: 10.1158/1078-0432.ccr-17-0478

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mechanisms of Primary Drug Resistance in FGFR1 -Amplified Lung CancerPMID 28630215Read ↗

RAS-MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR-MEK Blockade.Semantic proximity Read ↗

Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapySemantic proximity Read ↗

FGFR-driven lung cancer: Dissecting resistance and exploring therapeutic avenues.Semantic proximity Read ↗

Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR InhibitorsSemantic proximity Read ↗

Putative mechanisms of primary resistance to EGFR-targeted therapies: A retrospective study.Semantic proximity Read ↗

Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutationSemantic proximity Read ↗

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor <i>BRAF</i> gene mutations but lack mutations in <i>KRAS, NRAS,</i> or <i>MEK1</i>Semantic proximity Read ↗

Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.Semantic proximity Read ↗

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.Semantic proximity Read ↗

Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench.Semantic proximity Read ↗

Multiple resistant factors in lung cancer with primary resistance to EGFR-TK inhibitors confer poor survival.Semantic proximity Read ↗

Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.